---
title: "Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer"
description: "Basel, 18 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus sig"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261705568.md"
published_at: "2025-10-18T06:02:39.000Z"
---

# Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

> Basel, 18 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death ( progression-free survival.

Basel, 18 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death ( progression-free survival.

### Related Stocks

- [RHHBY.US - Roche](https://longbridge.com/en/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 罗杰斯｜8-K：2025 财年 Q4 营收 2.02 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276168131.md) |
| 惠誉在更新公司评级标准后维持了对 Hikma 和罗氏的评级 | 惠誉在更新企业评级标准后维持对 Hikma 和罗氏 (ADR) 的评级 | [Link](https://longbridge.com/en/news/275874477.md) |
| 罗氏公司任命马克·道森为罗氏制药研究与早期开发部门的新负责人 | 罗氏控股公司：罗氏控股公司 - 任命马克·道森（Mark Dawson），医学博士，哲学博士，担任罗氏制药研究与早期开发（PRED）新负责人，任命自 2026 年 5 月 1 日起生效 | [Link](https://longbridge.com/en/news/276097246.md) |
| 罗氏报告 2025 财年归属净收入和销售额增长 | 罗氏报告 FY25 可归属净收入和销售额增长 | [Link](https://longbridge.com/en/news/274100655.md) |
| 罗氏的 Gazyva 在晚期肾病研究中达成了主要目标 | 罗氏的 Gazyva 在晚期肾病研究中达成主要目标 | [Link](https://longbridge.com/en/news/276037536.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.